OSTADAN OMEAD
Known title: President & COOCIK: 0001642678
Associated companies
Transaction History
| SEER | ▼ Sell | Open Market | 4,441 | $36K | 5/27/2022 | View on chart |
| SEER | ▼ Sell | Open Market | 52,042 | $530K | 4/20/2022 | View on chart |
| SEER | ▲ Buy | Grant | 62,000 | $0 | 2/8/2022 | View on chart |
| SEER | ▲ Buy | Option Exercise | 20,000 | $54K | 12/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 9,220 | $206K | 12/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 5,407 | $126K | 12/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 5,373 | $130K | 12/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 17,200 | $523K | 11/15/2021 | View on chart |
| SEER | ▲ Buy | Option Exercise | 20,000 | $54K | 11/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 2,800 | $87K | 11/15/2021 | View on chart |
| SEER | ▲ Buy | Option Exercise | 20,000 | $54K | 10/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 8,604 | $282K | 10/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 11,396 | $378K | 10/15/2021 | View on chart |
| SEER | ▼ Sell | Other | 20,000 | $54K | 9/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 5,121 | $206K | 9/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 12,620 | $518K | 9/15/2021 | View on chart |
| SEER | ▼ Sell | Open Market | 2,259 | $95K | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced
Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced. Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.